Coexpression of Smad7 and UPA attenuates carbon tetrachloride-induced rat liver fibrosis

Medical Science Monitor

Volumn 18, Issue 10, 2012, Pages

  Wang, Baocan ^a   Li, Wenxi ^b   Chen, Yingwei ^a   Wang, Yuqin ^a   Sun, Chao ^a   Chen, Yuanwen ^a   Lu, Hanming ^a   Fan, Jiangao ^a   Li, Dingguo ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b China Novartis Institutes for BioMedical Research Co Ltd   (China)

Author keywords

Gene therapy; Smad7; Urokinase plasminogen activator; Ver fibrosis

Indexed keywords

ADENOVIRUS VECTOR; ALPHA SMOOTH MUSCLE ACTIN; BIOLOGICAL MARKER; CARBON TETRACHLORIDE; COLLAGENASE 3; CYCLINE; FIBRILLAR COLLAGEN; HYDROXYPROLINE; MESSENGER RNA; SCATTER FACTOR; SMAD7 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CLONING; COMBINATIONAL GENE THERAPY; CONTROLLED STUDY; DISEASE MARKER; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE OVEREXPRESSION; GENE THERAPY; HISTOPATHOLOGY; HUMAN CELL CULTURE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER FIBROSIS; MALE; NONHUMAN; PROTEIN DEGRADATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; ZYMOGRAPHY;

EID: 84867593745     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.883479     Document Type: Article

References (43)

1. Friedman SL: Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol, 2010; 7(8): 425-436
2. Matsuzaki K: Modulation of TGF-beta signaling during progression of chronic liver diseases. Front Biosci, 2009; 14: 2923-34
3. Ueberham E, Low R, Ueberham U et al: Conditional tetracycline-regulated expression of TGF-beta1 in liver of transgenic mice leads to reversible intermediary fibrosis. Hepatology, 2003; 37(5): 1067-78
4. Black D, Lyman S, Qian T et al: Transforming growth factor beta mediates hepatocyte apoptosis through Smad3 generation of reactive oxygen species. Biochimie, 2007; 89(12): 1464-73
5. Yuan W, Varga J: Transforming growth factor-beta repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3. J Biol Chem, 2001; 276(42): 38502-10
6. Ogawa K, Chen F, Kuang C, Chen Y: Suppression of matrix metalloproteinase-9 transcription by transforming growth factor-beta is mediated by a nuclear factor-kappaB site. Biochem J, 2004; 381(Pt 2): 413-22
7. Akool el S, Doller A, Muller R et al: Nitric oxide induces TIMP-1 expression by activating the transforming growth factor beta-Smad signaling pathway. J Biol Chem, 2005; 280(47): 39403-16
8. Min AK, Kim MK, Seo HY et al: Alpha-lipoic acid inhibits hepatic PAI-1 expression and fibrosis by inhibiting the TGF-beta signaling pathway. Biochem Biophys Res Commun, 2010; 393(3): 536-41
9. Dooley S, Hamzavi J, Ciuclan L et al: Hepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damage. Gastroenterology, 2008; 135(2): 642-59
10. Dooley S, Delvoux B, Lahme B et al: Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. Hepatology, 2000; 31(5): 1094-106
11. Mondino A, Blasi F: uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol, 2004; 25(8): 450-55
12. Smith HW, Marshall CJ: Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol, 2010; 11(1): 23-36
13. Plouet J, Moro F, Bertagnolli S et al: Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J Biol Chem, 1997; 272(20): 13390-96
14. Mars WM, Jo M, Gonias SL: Activation of hepatocyte growth factor by urokinase-type plasminogen activator is ionic strength-dependent. Biochem J, 2005; 390(Pt 1): 311-15
15. Carmeliet P, Schoonjans L, Kieckens L et al: Physiological consequences of loss of plasminogen activator gene function in mice. Nature, 1994; 368(6470): 419-24
16. Shanmukhappa K, Sabla GE, Degen JL, Bezerra JA: Urokinase-type plasminogen activator supports liver repair independent of its cellular receptor. BMC Gastroenterol, 2006; 6: 40
17. Currier AR, Sabla G, Locaputo S et al: Plasminogen directs the pleiotropic effects of uPA in liver injury and repair. Am J Physiol Gastrointest Liver Physiol, 2003; 284(3): G508-15
18. Jiang D, Xu C, Li Z et al: Protective action of hepatocyte growth factor on transforming growth factor beta-1-induced alpha-smooth muscle actin and extracellular matrix in cultured human peritoneal fibroblasts. Med Sci Monit, 2010; 16(8): BR250-54
19. Pohl JF, Melin-Aldana H, Sabla G et al: Plasminogen deficiency leads to impaired lobular reorganization and matrix accumulation after chronic liver injury. Am J Pathol, 2001; 159(6): 2179-86
20. Chan JC, Duszczyszyn DA, Castellino FJ, Ploplis VA: Accelerated skin wound healing in plasminogen activator inhibitor-1-deficient mice. Am J Pathol, 2001; 159(5): 1681-88
21. Leyland H, Gentry J, Arthur MJ, Benyon RC: The plasminogen-activating system in hepatic stellate cells. Hepatology, 1996; 24(5): 1172-78
22. Gonzalez-Cuevas J, Bueno-Topete M, Armendariz-Borunda J: Urokinase plasminogen activator stimulates function of active forms of stromelysin and gelatinases (MMP-2 and MMP-9) in cirrhotic tissue. J Gastroenterol Hepatol, 2006; 21(10): 1544-54
23. Cotter MJ, Muruve DA: The induction of inflammation by adenovirus vectors used for gene therapy. Front Biosci, 2005; 10: 1098-105
24. Na M, Fan X: Design of Ad5F35 vectors for coordinated dual gene expression in candidate human hematopoietic stem cells. Exp Hematol, 2010; 38(6): 446-52
25. Rees S, Coote J, Stables J et al: Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. Biotechniques, 1996; 20(1): 102-4, 106, 108-10
26. Green NK, McNeish IA, Doshi R et al: Immune enhancement of nitroreductase-induced cytotoxicity: studies using a bicistronic adenovirus vector. Int J Cancer, 2003; 104(1): 104-12
27. Piotrowski WJ, Górski P, Pietras T et al: The selected genetic polymorphisms of metalloproteinases MMP2, 7, 9 and MMP inhibitor TIMP2 in sarcoidosis. Med Sci Monit, 2011; 17(10): CR598-607
28. James J, Bosch KS, Aronson DC, Houtkooper JM: Sirius red histophotometry and spectrophotometry of sections in the assessment of the collagen content of liver tissue and its application in growing rat liver. Liver, 1990; 10(1): 1-5
29. Yoshiji H, Kuriyama S, Yoshii J et al: Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology, 2002; 36(4 Pt 1): 850-60
30. Lu P, Liu H, Yin H, Yang L: Expression of angiotensinogen during hepatic fibrogenesis and its effect on hepatic stellate cells. Med Sci Monit, 2011; 17(9): BR248-56
31. Carpino G, Morini S, Ginanni Corradini S et al: Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Dig Liver Dis, 2005; 37(5): 349-56
32. Gressner AM: Cytokines and cellular crosstalk involved in the activation of fat-storing cells. J Hepatol, 1995; 22(Suppl.2): 28-36
33. Hironaka K, Sakaida I, Matsumura Y et al: Enhanced interstitial collagenase (matrix metalloproteinase-13) production of Kupffer cell by gadolinium chloride prevents pig serum-induced rat liver fibrosis. Biochem Biophys Res Commun, 2000; 267(1): 290-95
34. Apte UM, McRee R, Ramaiah SK: Hepatocyte proliferation is the possible mechanism for the transient decrease in liver injury during steatosis stage of alcoholic liver disease. Toxicol Pathol, 2004; 32(5): 567-76
35. Shek FW, Benyon RC: How can transforming growth factor beta be targeted usefully to combat liver fibrosis? Eur J Gastroenterol Hepatol, 2004; 16(2): 123-26
36. Arias M, Lahme B, Van de Leur E et al: Adenoviral delivery of an antisense RNA complementary to the 3' coding sequence of transforming growth factor-beta1 inhibits fibrogenic activities of hepatic stellate cells. Cell Growth Differ, 2002; 13(6): 265-73
37. Ozawa S, Uchiyama K, Nakamori M et al: Combination gene therapy of HGF and truncated type II TGF-beta receptor for rat liver cirrhosis after partial hepatectomy. Surgery, 2006; 139(4): 563-73
38. de Gouville AC, Boullay V, Krysa G et al: Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. Br J Pharmacol, 2005; 145(2): 166-77
39. Bueno M, Salgado S, Beas-Zarate C, Armendariz-Borunda J: Urokinasetype plasminogen activator gene therapy in liver cirrhosis is mediated by collagens gene expression down-regulation and up-regulation of MMPs, HGF and VEGF. J Gene Med, 2006; 8(11): 1291-99
40. Iwamoto H, Sakai H, Tada S et al: Induction of apoptosis in rat hepatic stellate cells by disruption of integrin-mediated cell adhesion. J Lab Clin Med, 1999; 134(1): 83-89
41. Ueki T, Kaneda Y, Tsutsui H et al: Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med, 1999; 5(2): 226-30
42. Halder SK, Beauchamp RD, Datta PK: Smad7 induces tumorigenicity by blocking TGF-beta-induced growth inhibition and apoptosis. Exp Cell Res, 2005; 307(1): 231-46
43. Inagaki Y, Kushida M, Higashi K et al: Cell type-specific intervention of transforming growth factor beta/Smad signaling suppresses collagen gene expression and hepatic fibrosis in mice. Gastroenterology, 2005; 129(1): 259-68